Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the zostavax market grown in recent years?

Over the recent years, the market size for zostavax has experienced an increase of XX (HCAGR). Projections indicate that it will expand from $XX million in 2024, reaching $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. The growth observed during the historic period can be associated with the expansion in preventive healthcare measures, enhanced vaccine accessibility, increased insurance coverage, improved awareness regarding shingles and its complications, and the integration of shingles vaccines in national immunization agendas.

How is the zostavax market size expected to evolve during the forecast period?

In the coming years, the Zostavax market is projected to see an increase of XX% (FCAGR), reaching a valuation of $XX million by 2029 at a Compound Annual Growth Rate (CAGR) of XX%. Factors contributing to this growth during the forecast period include increased shingles vaccine approvals from regulatory bodies, cost-effectiveness of vaccines compared to treatments, widespread acceptance of shingrix among developed nations, and mounting prevalence of chronic diseases. Foreseen trends include a transition to more advanced products, heightened vaccine research and development ventures by companies, government campaigns and endeavors for public health, extension programs targeted at rural regions to raise awareness and availability of shingles vaccines, and technological progressions.

Get your zostavax market report here!

https://www.thebusinessresearchcompany.com/report/zostavax-global-market-report

Which key drivers are propelling the zostavax market’s growth?

The anticipated increase in healthcare infrastructure in developing nations is predicted to boost the growth of the zostavax market. Healthcare infrastructure comprises a unified network of personnel, systems, equipment, and facilities needed to provide effective and efficient healthcare services to a community. The reason behind the growing healthcare infrastructure in developing nations is largely attributed to the increasing investments in healthcare facilities and enhanced access to medical services. Healthcare infrastructure aids zostavax by offering requisite facilities, resources, and systems needed to distribute the vaccine to the targeted people, especially in hospitals, clinics, and pharmacies. For instance, the Department of Health and Social Care, a UK government department, announced in May 2023 that the UK government has confirmed an investment of over $25.33 billion (£20 billion) in the New Hospital Programme, aimed at fulfilling the commitment to construct 40 new hospitals in England by 2030. Moreover, this program includes plans for three mental health hospitals in an overall strategy to phase out dormitory accommodations in mental health institutions and advance equality in both physical and mental healthcare. Two hospitals have been finished till date, five are under construction and over 20 are slated to commence or be finished by the closure of the next year. Consequently, the escalated expansion of healthcare infrastructure in developing nations stimulates the growth of the zostavax market.

What are the market segments in the zostavax industry?

The zostavax market covered in this report is segmented –

1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)

2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20374&type=smp

Which leading companies are shaping the growth of the zostavax market?

Major companies operating in the zostavax market are Merck & Co. Inc.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20374

Which geographic areas are influencing the growth of the zostavax market?

North America was the largest region in the zostavax market in 2024. The regions covered in the zostavax market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chickenpox Vaccine Global Market Report 2025

https://thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Cell and Gene Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Herpes Simplex Virus Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/herpes-simplex-virus-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: